You just read:

Janssen Inc. Announces IMBRUVICA® (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review

News provided by

Janssen Inc.

Oct 30, 2017, 07:30 ET